Previous Close | 7.22 |
Open | 7.31 |
Bid | 7.40 x 200 |
Ask | 7.46 x 100 |
Day's Range | 7.18 - 7.53 |
52 Week Range | 6.08 - 11.91 |
Volume | |
Avg. Volume | 1,854,286 |
Market Cap | 608.695M |
Beta (5Y Monthly) | 2.05 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.02 |
Earnings Date | May 03, 2024 - May 07, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.86 |
Subscribe to Yahoo Finance Plus to view Fair Value for EDIT
The company now has a chance to get its lead program out the door a bit sooner.
Editas Medicine Inc (NASDAQ:EDIT), a leading genome editing company, focuses on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world.
The biotech has bounced back some in the past year.